In instances where surgical aortic valve replacement (AVR) carries heightened risks, particularly for patients aged 75 and older or those with significant comorbidities making surgery unsafe, the transfemoral aortic valve replacement (TAVR) emerges as a viable alternative. This innovative procedure involves the introduction of a collapsible valve through the femoral artery in the leg, obviating the need for general anesthesia, blood transfusion, or any surgical incisions. It is imperative to underscore that patient suitability for TAVR hinges on a thorough evaluation, often including a CT scan to discern the specific nuances of each case.
TAVR proves especially advantageous for elderly individuals, typically aged 70 or older, who present with a myriad of comorbidities, including respiratory or other health issues, which might render traditional surgery less feasible. One notable advantage of TAVR lies in its ability to facilitate valve replacement without necessitating surgery, incisions, or the need for ventilatory support or intensive care unit (ICU) admission. This approach marks a significant stride in providing effective and less invasive options for patients facing challenges with traditional surgical interventions.
